眾生藥業(002317.SZ)：控股子公司獲得國際專利證書
格隆匯11月30日丨眾生藥業(002317.SZ)公佈，近日，公司控股子公司廣東眾生睿創生物科技有限公司(“眾生睿創”)分別收到美國專利商標局(United States Patent and Trademark Office)和日本特許廳(Japan Patent Office)頒發的專利證書。具體情況如下：
ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVE(抗流感病毒嘧啶衍生物)是眾生睿創開發的用於預防和治療甲型流感及人禽流感的一類創新藥物ZSP1273 項目的化合物專利，屬於該項目的核心專利。ZSP1273 項目是國內首個獲批臨牀試驗的治療甲型流感的小分子RNA 聚合酶抑制劑，目前正在開展治療成人單純性甲型流感的III期臨牀試驗，以進一步確證其療效和安全性。ZSP1273顆粒劑已獲得國家藥品監督管理局核發的《藥物臨牀試驗批准通知書》，正積極準備開展用於兒童的單純性流感II期臨牀研究。
ＰＰＡＲアゴニストとして用いられるピロリジン誘導體の非晶質及びその製造方法(作為PPAR激動劑的吡咯烷衍生物的無定形及其製備方法)是眾生睿創在肝病領域佈局的一類創新藥物ZSP0678項目的晶型專利，屬於該項目的核心專利。ZSP0678是眾生睿創研發的具有明確作用機制並具有自主知識產權的用於治療非酒精性脂肪性肝炎(NASH)和原發性膽汁性膽管炎(PBC)的創新藥物。目前，ZSP0678片用於治療NASH臨牀試驗已獲得國家藥品監督管理局(NMPA)的批准，正處於撰寫I期臨牀研究總結報吿階段。ZSP0678片用於治療原發性膽汁性膽管炎(PBC)的新增適應症臨牀試驗已獲得國家藥品監督管理局核發的《臨牀試驗通知書》，臨牀試驗的工作將按計劃組織實施。
截至目前，ZSP1273項目化合物專利已經獲得中國、美國、日本、韓國、澳大利亞、新西蘭、俄羅斯、新加坡、南非、香港特別行政區、澳門特別行政區等國家/地區的專利授權；ZSP0678項目晶型專利已經獲得澳大利亞、俄羅斯、日本等國家/地區的專利授權，公司創新藥項目的全球知識產權保護體系逐漸完善。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
